Japanese and German neuropathology traditions have produced highly influential case series on corticobasal degeneration (CBD), contributing critical insights into clinical presentation, disease progression, and diagnostic markers. These series represent some of the largest pathologically-confirmed cohorts worldwide.
The Japanese Validation study of Autopsy-proven Corticobasal degeneration (J-VAC) has produced several landmark publications:
Clinical Course of Pathologically Confirmed CBD (PMID 38090279)
- Median survival time: 7.0 years from symptom onset
- 50% of patients diagnosed as CBD/CBS at final presentation
- Key clinical features: asymmetric rigidity, apraxia, cortical sensory loss
- Published 2023
MRI Features Distinguishing CBD (PMID 39039147)
- Retrospective analysis of 19 pathologically-confirmed CBD patients vs 16 mimics
- Identified key imaging markers for differential diagnosis
- Focused on cortical atrophy patterns and white matter changes
Clinical Characteristics of Japanese CBD Patients (PMID 39243604)
- Explored phenotypic variations in Japanese population
- Pathological investigations essential for definitive diagnosis
- Published 2024
Japanese Longitudinal Biomarker Study (PMID 39534091)
- Multicenter prospective registry study initiated in 2014
- Clinical features analysis of Japanese PSP and CBD patients
- Biomarker correlates including CSF and imaging markers
| Researcher |
Institution |
Key Contributions |
| Iwasaki Y |
Nagasaki University |
Pathological characterization |
| Yoshida M |
Kinoura University |
Neuropathology of CBD |
| Mizusawa H |
Tokyo Medical and Dental University |
Historical reviews |
| Aiba I |
National Hospital Organization |
J-VAC lead |
| Sone J |
Kanazawa University |
Clinical biomarkers |
¶ GWAS and Genetic Studies
The German research group led by Günter Höglinger (Munich) has produced foundational genetic studies:
Genome-Wide Association Study (PMID 26077951)
- Analyzed 152 CBD cases and 3,311 controls
- Identified risk variants shared with progressive supranuclear palsy
- First large-scale genetic study of CBD
- Key finding: significant overlap in genetic risk factors between CBD and PSP
Shared Genetic Risk (PMID 28271184)
- Demonstrated genetic overlap between CBD and PSP
- Also found shared risk with frontotemporal dementia
- Suggests common underlying pathogenic mechanisms
Differentiation of Atypical Parkinson Syndromes (PMID 28243754)
- Reviews diagnostic criteria for CBD, PSP, MSA, DLB
- Clinical features distinguishing these conditions
- Important for accurate diagnosis during life
| Institution |
Key Focus |
| LMU Munich |
Genetics, clinical trials |
| University of Tübingen |
Neuroimaging |
| Charité Berlin |
Clinical characterization |
Several significant 2024 publications have expanded our understanding:
Inferior Olivary Nucleus Hypertrophy (PMID 38818729)
- Japanese cohort study from Tahara et al.
- Documents hypertrophy of the inferior olivary nucleus in pathologically confirmed CBD
- Neuropathological finding with potential diagnostic value
- Published in Clinical Neuropathology (2024)
Subcortical Tau and Hypoperfusion (PMID 38842726)
- European multi-center study (Roemer et al.)
- 25 CBS patients and 26 PSP patients
- Demonstrates link between subcortical tau accumulation and cortical hypoperfusion
- Important for understanding disease propagation mechanisms
| Feature |
Japanese Series |
Western Series |
| Age at onset |
~60-65 years |
~60-70 years |
| Disease duration |
7-8 years |
6-8 years |
| Apraxia prevalence |
70-80% |
60-70% |
| Cortical sensory loss |
40-50% |
30-40% |
Both Japanese and German series emphasize:
- Clinical-pathological correlation: CBS during life often does not correlate with CBD at autopsy
- Phenotypic variability: Significant overlap with PSP, FTD, and DLB
- Biomarker importance: MRI, PET, and CSF markers increasingly important for antemortem diagnosis
Findings from Japanese and German case series directly inform current therapeutic strategies:
Both Japanese and German neuropathology studies confirm the predominance of 4R-tau filaments in CBD, sharing this feature with PSP. This genetic and pathological overlap suggests:
- Common therapeutic targets: Anti-tau antibodies, tau aggregation inhibitors, and tau-targeted immunotherapy may benefit both CBD and PSP patients
- MAPT genetic risk factor: The H1 haplotype identified in the German GWAS is shared with PSP, making MAPT a high-priority target
- Early diagnosis importance: Japanese series demonstrate that earlier clinical recognition enables enrollment in disease-modifying trials before extensive neuronal loss
The Höglinger group (Munich) coordinates several CBD-focused trials targeting:
Based on Japanese case series data:
- Typical symptom duration: 1-5 years from onset (best window for neuroprotective trials)
- Key inclusion: asymmetric apraxia, cortical sensory loss, alien limb phenomenon
- Key exclusion: significant memory impairment suggesting AD-type pathology
The 2024 Japanese study by Tahara et al. documents a finding unique to CBD among 4R-tauopathies:
- Hypertrophy of the inferior olivary nucleus observed in pathologically confirmed CBD
- Not seen in PSP or other tauopathies
- Suggests specific vulnerability of olivary circuitry in CBD
- Potential diagnostic histopathological marker
- May relate to the characteristic "tectal" eye movement abnormalities in CBD
¶ Subcortical Tau and Hypoperfusion (PMID 38842726)
The European multi-center study demonstrates:
- Direct link between subcortical tau accumulation and cortical hypoperfusion
- 25 CBS patients and 26 PSP patients examined
- Suggests tau spreads along neural networks, causing remote hypometabolism
- Supports the "prion-like" propagation model of tau pathology
- Has implications for PET imaging biomarkers — tau PET may reflect network-based spread